Ovarian Epithelial Cancer

Also known as: Epithelial Ovarian Cancer / Ovarian epithelial cancer NOS

DrugDrug NameDrug Description
DB01006LetrozoleLetrozole (INN, trade name Femara®) is an oral non-steroidal aromatase inhibitor that has been introduced for the adjuvant treatment of hormonally-responsive breast cancer Estrogens are produced by the conversion of androgens through the activity of the aromatase enzyme. Letrozole blocks the production of estrogens in this way by competitive, reversible binding to the heme of its cytochrome P450 unit. It is important to note that letrozole does not decrease the production of mineralocorticoids or corticosteroids. In contrast, the antiestrogenic action of tamoxifen, the major medical therapy prior to the arrival of aromatase inhibitors, is due to its interfering with the estrogen receptor, rather than inhibiting estrogen production. Side effects include signs and symptoms of hypoestrogenism. There is concern that long term use may lead to osteoporosis, which is why prescriptions of Letrozole are often accompanied by prescriptions of osteoporosis-fighting medication such as Fosamax. Letrozole has shown to reduce estrogen levels by 98 percent while raising testosterone levels. The anti-estrogen action of letrozole is preferred by athletes and bodybuilders for use during a steroid cycle to reduce bloating due to excess water retention and prevent the formation of gynecomastia related breast tissue that is a side effect of some anabolic steroids. Usage above 2.5 mg/day is known to potentially temporarily kill sex drive. Above 5mg/day for extended periods may cause kidney problems. Letrozole has also been shown to delay the fusing of the growth plates in adolescents. This may boost the effectiveness of growth hormone, and thus Letrozole is used to treat adolescents and children with short stature.
DB01042MelphalanAn alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - melphalan, the racemic mixture - merphalan, and the dextro isomer - medphalan; toxic to bone marrow, but little vesicant action; potential carcinogen.
DB11793NiraparibNiraparib is an orally active PARP inhibitor developed by Tesaro to treat ovarian cancer. FDA approval on March 2017.
DB09074OlaparibOlaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasis and cell death. Olaparib is available as oral tablets marketed under the brand name Lynparza and was initially indicated as a maintenance therapy or monotherapy for the treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. On January 12, 2018, FDA expanded the approved use of Lynparza to include chemotherapy-experienced patients with germline breast cancer susceptibility gene (BRCA) mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. In a randomized clinical trial involving patients with HER2-negative metastatic breast cancer with a germline BRCA mutation, the median progression-free survival for patients taking Lynparza was 7 months compared to 4.2 months for patients taking chemotherapy only. Patient selection for this newly-approved indication can be performed based on an FDA-approved genetic test, called the BRACAnalysis CDx. Moreover, in December of 2018 the FDA further approved the categorization and use of Lynparza (olaparib) as frontline maintenance therapy in ovarian cancer, making the medication the first time a PARP inhibitor has been approved in the first-line maintenance setting [L5086]. This new approval for frontline maintenance now allows patients who have had surgery and complete or partial response to platinum-based therapy after being first diagnosed with the cancer to be treated with olaparib to decrease the risk of recurrence or delay it significantly [L5086]. This approval is based on findings from the phase 3 SOLO-1 trial for olaparib, which demonstrated the capacity for the agent to reduce the risk of disease progression or death by 70% in patients with BRCA-mutant advanced ovarian cancer who were in complete or partial response to platinum-based chemotherapy [L5086]. It is expected that the ability to offer this important first-line maintenance treatment option to eligible patients may slow down or even stop the natural course of disease progression [L5086].
DrugDrug NamePhaseStatusCount
DB09037Pembrolizumab0Active Not Recruiting1
DB11945Avelumab1Terminated1
DB00112Bevacizumab1Terminated1
DB11967Binimetinib1Completed1
DB00958Carboplatin1Completed3
DB00958Carboplatin1Not Yet Recruiting1
DB00958Carboplatin1Withdrawn1
DB01413Cefepime1Completed1
DB00515Cisplatin1Completed1
DB00531Cyclophosphamide1Active Not Recruiting1
DB12282Defactinib1Terminated1
DB00997Doxorubicin1Terminated1
DB11714Durvalumab1Not Yet Recruiting1
DB05595Farletuzumab1Completed2
DB00441Gemcitabine1Completed1
DB06721Gimatecan1Recruiting1
DB14865Human interleukin-21Recruiting1
DB00480Lenalidomide1Terminated1
DB00331Metformin1Completed1
DB12807Naptumomab Estafenatox1Not Yet Recruiting1
DB01229Paclitaxel1Completed3
DB01229Paclitaxel1Not Yet Recruiting1
DB01229Paclitaxel1Withdrawn1
DB12985Quisinostat1Completed1
DB11805Saracatinib1Withdrawn1
DB11945Avelumab1 / 2Completed1
DB05015Belinostat1 / 2Completed1
DB00112Bevacizumab1 / 2Active Not Recruiting1
DB00958Carboplatin1 / 2Active Not Recruiting1
DB00958Carboplatin1 / 2Completed2
DB00958Carboplatin1 / 2Recruiting1
DB00515Cisplatin1 / 2Terminated1
DB00531Cyclophosphamide1 / 2Completed1
DB00997Doxorubicin1 / 2Active Not Recruiting1
DB11841Entinostat1 / 2Completed1
DB12047Ganetespib1 / 2Terminated1
DB00441Gemcitabine1 / 2Completed1
DB12489Mirvetuximab Soravtansine1 / 2Active Not Recruiting1
DB09035Nivolumab1 / 2Recruiting1
DB04964Oregovomab1 / 2Recruiting1
DB01229Paclitaxel1 / 2Completed1
DB01229Paclitaxel1 / 2Recruiting1
DB01229Paclitaxel1 / 2Terminated1
DB06589Pazopanib1 / 2Completed1
DB09037Pembrolizumab1 / 2Active Not Recruiting1
DB11787Ralimetinib1 / 2Completed1
DB12893Sacituzumab govitecan1 / 2Active Not Recruiting1
DB00928Azacitidine2Recruiting1
DB12459Belotecan2Completed1
DB00112Bevacizumab2Active Not Recruiting1
DB00112Bevacizumab2Completed1
DB00112Bevacizumab2Recruiting3
DB00112Bevacizumab2Terminated1
DB11782Birinapant2Completed1
DB00958Carboplatin2Active Not Recruiting1
DB00958Carboplatin2Completed3
DB00958Carboplatin2Recruiting6
DB00958Carboplatin2Suspended1
DB00958Carboplatin2Terminated1
DB00958Carboplatin2Unknown Status1
DB06607Catumaxomab2Completed1
DB00515Cisplatin2Completed1
DB00515Cisplatin2Not Yet Recruiting1
DB00515Cisplatin2Recruiting2
DB00004Denileukin diftitox2Completed1
DB00004Denileukin diftitox2Terminated1
DB00997Doxorubicin2Active Not Recruiting1
DB00997Doxorubicin2Completed1
DB00997Doxorubicin2Recruiting2
DB11714Durvalumab2Recruiting1
DB00773Etoposide2Recruiting1
DB05595Farletuzumab2Completed1
DB00441Gemcitabine2Completed2
DB00441Gemcitabine2Recruiting2
DB00762Irinotecan2Recruiting1
DB04845Ixabepilone2Recruiting1
DB06448Lonafarnib2Completed1
DB11740MK-17752Unknown Status1
DB05477MUC1 Dendritic Cell Vaccine2Completed2
DB05477MUC1 Dendritic Cell Vaccine2Terminated1
DB12303Motolimod2Active Not Recruiting1
DB09035Nivolumab2Recruiting1
DB09074Olaparib2Recruiting2
DB01229Paclitaxel2Active Not Recruiting1
DB01229Paclitaxel2Completed5
DB01229Paclitaxel2Not Yet Recruiting1
DB01229Paclitaxel2Recruiting6
DB01229Paclitaxel2Terminated1
DB01269Panitumumab2Completed1
DB06589Pazopanib2Completed1
DB09037Pembrolizumab2Active Not Recruiting1
DB09037Pembrolizumab2Recruiting2
DB00642Pemetrexed2Recruiting1
DB12060RRx-0012Recruiting1
DB12332Rucaparib2Active Not Recruiting1
DB12332Rucaparib2Recruiting1
DB11857Seribantumab2Completed1
DB01030Topotecan2Completed2
DB01030Topotecan2Recruiting1
DB00361Vinorelbine2Recruiting1
DB11999Vosaroxin2Completed1
DB00958Carboplatin2 / 3Active Not Recruiting1
DB01229Paclitaxel2 / 3Active Not Recruiting1
DB00112Bevacizumab3Not Yet Recruiting1
DB00958Carboplatin3Recruiting2
DB00958Carboplatin3Unknown Status1
DB00515Cisplatin3Recruiting1
DB00997Doxorubicin3Active Not Recruiting1
DB00997Doxorubicin3Terminated1
DB00099Filgrastim3Recruiting1
DB00441Gemcitabine3Recruiting1
DB12489Mirvetuximab Soravtansine3Active Not Recruiting1
DB09035Nivolumab3Recruiting1
DB09074Olaparib3Recruiting1
DB01229Paclitaxel3Active Not Recruiting1
DB01229Paclitaxel3Completed1
DB01229Paclitaxel3Recruiting2
DB01229Paclitaxel3Unknown Status1
DB12332Rucaparib3Recruiting2
DB01030Topotecan3Active Not Recruiting1
DB01030Topotecan3Terminated1
DB15237Fluciclovine4Recruiting1
DB13146Fluciclovine (18F)4Recruiting1
DB00112BevacizumabNot AvailableCompleted1
DB00958CarboplatinNot AvailableCompleted1
DB00515CisplatinNot AvailableTerminated1
DB00997DoxorubicinNot AvailableCompleted1
DB01229PaclitaxelNot AvailableCompleted1